Repository logo
 
Publication

Novel delivery systems for anti-allergic agents: allergic disease and innovative treatments

2015-07-29Journal article Restricted access
Simple item page
dc.contributor.authorLopes, Carla Martins
dc.contributor.authorCoelho, Pedro
dc.contributor.authorOliveira, Rita
dc.date.accessioned2020-10-13T09:56:15Z
dc.date.available2020-10-13T09:56:15Z
dc.date.issued2015-07-29
dc.date.updated2020-07-24T15:42:26Z
dc.description.abstractAnti-allergic agents are used to treat a great variety of diseases which usually involve an inflammation reaction. These compounds act by inhibiting the release and the effects of inflammatory mediators (e.g. histamine) in the target tissue. The purpose of anti-allergy therapy is to deliver the drug to its local of action in a therapeutic concentration, minimizing the undesired side effects. In order to solve some of the anti-allergic agents’ physicochemical drawbacks and the limitations associated to conventional pharmaceutical formulations (e.g. poor solubility and absorption, skin permeation, stability), novel drug delivery systems, such as cyclodextrins, liposomes, micelles, microemulsions, nano and microparticles, have been developed. Depending on the allergic condition, several administration routes are used to deliver anti-allergic agents, each with its own disadvantages to overcome. In the literature, there are a vast number of papers concerning novel delivery systems for anti-allergic agents, making it difficult to evaluate the information and the promising outcomes. The aim of the present review article is to compile the recent (i.e. in the new millennium) improvements of novel drug delivery technology focusing on the achievement of anti-allergic therapeutic delivery. The potential intrinsic benefits of these systems will reflect an increased therapeutic adherence and better patients’ life quality. A critical prospect of future clinical trial directions will also be discussed.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.2174/1567201812666150421111222pt_PT
dc.identifier.issn1567-2018
dc.identifier.slugcv-prod-1252827
dc.identifier.urihttp://hdl.handle.net/10284/9051
dc.language.isoengpt_PT
dc.publisherBentham Science Publisherspt_PT
dc.subjectAdministration routespt_PT
dc.subjectAnti-allergic agentspt_PT
dc.subjectCorticosteroidspt_PT
dc.subjectH1-antihistaminespt_PT
dc.subjectMonoclonal antibodiespt_PT
dc.subjectNovel drug delivery systemspt_PT
dc.titleNovel delivery systems for anti-allergic agents: allergic disease and innovative treatmentspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage396pt_PT
oaire.citation.issue4pt_PT
oaire.citation.startPage382pt_PT
oaire.citation.titleCurrent Drug Deliverypt_PT
oaire.citation.volume12pt_PT
person.familyNameLopes
person.givenNameCarla
person.identifier.ciencia-id901D-160C-633E
person.identifier.orcid0000-0001-5080-032X
person.identifier.ridM-4689-2016
person.identifier.scopus-author-id26649517700
rcaap.cv.cienciaid901D-160C-633E | Carla Martins Lopes
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationd2a48cfe-9258-4916-99be-bbcb710f6605
relation.isAuthorOfPublication.latestForDiscoveryd2a48cfe-9258-4916-99be-bbcb710f6605

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Current_Drug_Delivery_2015_382-396.pdf
Size:
1.66 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCS (DCF) - Artigos em Revistas Científicas Internacionais com Arbitragem Científica